IC
CGEM icon

Inscription Capital’s Cullinan Oncology CGEM Stock Holding History

Inscription Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$166K Hold
11,661
– – 0.02% 638
2025
Q4 		$121K Buy
11,661
+377
+3% +$3.4K 0.01% 644
2025
Q3 		$66.9K Buy
+11,284
New +$82.6K 0.01% 629

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Inscription Capital's CGEM Position: Q1 2026 in Review

Inscription Capital held its Cullinan Oncology (CGEM) position steady in Q1 2026 at 11,661 shares worth $166K. The position accounts for 0.02% of the portfolio, ranked #638.

Inscription Capital first reported a position in CGEM in Q3 2025 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Inscription Capital held 11,661 shares of Cullinan Oncology worth $166K as of Q1 2026.
  • Inscription Capital left its Cullinan Oncology share count unchanged in Q1 2026.
  • Cullinan Oncology made up 0.02% of Inscription Capital's portfolio in Q1 2026, its #638 holding.
  • Inscription Capital first reported a position in Cullinan Oncology in Q3 2025 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Inscription Capital's 13F filing for Q1 2026, filed 20 Apr 2026.